TABLE 3.

Resistance rates for the most common gram-positive cocci isolated from Canadian ICUs

Organisma and specimen source% of isolates intermediate/% of isolates resistant to the following antimicrobialb:
CFZCPMCTRCLRCDLZDTGCCIPLEVMXFMERPTZSXTDAPVAN
S. aureus
    MSSA
        All0/00/00.4/00.3/20.10/4.40/00/01.3/7.90.2/7.30.9/6.40/00/00/0.60/00/0
        Blood0/00/01.2/00/16.10/4.60/00/01.2/6.90/6.90/6.90/00/00/00/00/0
        Urine0/00/00/00/30.00/10.00/00/00/20.00/20.05.0/15.00/00/00/00/00/0
        Wound0/00/00/00.9/23.90/3.50/00/01.8/8.00/7.10/7.10/00/00/1.80/00/0
        Respiratory0/00/00.4/00.2/19.50/4.30/00/01.3/7.50.2/6.91.1/5.80/00/00/0.40/00/0
    MRSA
        All0/100c0/100c0/100c0/89.90/76.10/00/00/91.80/91.81.0/90.10/100c0/100c0/11.70/00/0
        Blood0/100c0/100c0/100c0/93.90/79.60/00/00/91.80/91.82.0/89.80/100c0/100c0/4.10/00/0
        Urine0/100c0/100c0/100c0/1000/1000/00/00/1000/1000/1000/100c0/100c0/00/00/0
        Wound0/100c0/100c0/100c0/96.30/81.50/00/00/92.60/92.63.7/88.90/100c0/100c0/14.80/00/0
        Respiratory0/100c0/100c0/100c0/86.40/72.90/00/00/91.50/91.50/91.50/100c0/100c0/14.40/00/0
S. epidermidis
    MSSE
        All2.3/02.3/16.323.3/8.11.2/77.40/54.80/03.5/54.74.7/52.38.3/41.79.3/9.30/1.20/35.70/00/0
        Blood0/01.8/8.917.9/1.81.8/74.60/43.60/05.4/44.65.4/42.97.3/34.68.9/1.80/00/34.60/00/0
        Urine0/020.0/20.060.0/00/1000/1000/00/80.00/80.00/80.040.0/00/00/20.00/00/0
        Wound8.3/00/33.329.2/25.00/79.20/70.80/00/70.84.2/66.712.5/50.04.2/29.20/4.20/41.70/00/0
        Respiratory0/00/00/0NDNDND0/1000/100ND0/00/0NDND0/0
    MRSE
        All0/100c0/100c0/100c0/96.00/92.00/00/1000/1004.0/96.00/100c0/100c0/88.00/00/0
        Blood0/100c0/100c0/100c0/1000/1000/00/1000/10016.7/83.30/100c0/100c0/83.30/00/0
        Urine0/100c0/100c0/100c0/1000/1000/00/1000/1000/1000/100c0/100c0/1000/00/0
        Wound0/100c0/100c0/100c0/94.10/88.20/00/1000/1000/1000/100c0/100c0/88.20/00/0
        RespiratoryNANANANANANANANANANANANANANA
S. pneumoniae
    All0/00/03.4/15.90.4/5.60/00/2.10/1.70.4/1.34.3/0.47.3/8.60/0
    Blood0/00/00/13.20/2.60/00/00/00/08.1/05.3/10.50/0
    UrineNANANANANANANANANANANA
    Wound0/00/00/16.70/00/00/00/00/00/00/16.70/0
    Respiratory0/00/04.2/16.40.5/6.40/00/2.60/2.10.5/1.63.7/0.57.9/7.90/0
Enterococcus spp.
    All16.8/65.911.1/1.80.4/08.0/53.41.2/51.0−/21.10/00/6.8
    Blood18.6/68.617.1/2.90/09.5/58.10/56.8−/27.00/00/5.4
    Urine11.9/70.13.0/1.50/04.0/54.72.7/52.0−/17.30/00/4.0
    Wound20.6/60.314.3/1.61.4/011.1/50.01.4/45.8−/22.20/00/12.5
    Respiratory15.4/61.57.7/00/06.7/46.70/46.7−/13.30/00/3.3
  • a MSSE, methicillin-sensitive S. epidermidis; MRSE, methicillin-resistant S. epidermidis.

  • b Antimicrobial abbreviations: CFZ, cefazolin; CPM, cefepime; CTR, ceftriaxone; CLR, clarithromycin; CD, clindamycin; LZD, linezolid; TGC, tigecycline; CIP, ciprofloxacin; LEV, levofloxacin; MXF, moxifloxacin; MER, meropenem; PTZ-piperacillin-tazobactam; SXT, trimethoprim-sulfamethoxazole; DAP, daptomycin; VAN, vancomycin. CLSI breakpoints for Enterococcus spp. and ampicillin (sensitive [S], ≤8μg/ml; resistant [R], ≥16 μg/ml) were applied to piperacillin-tazobactam, and erythromycin breakpoints (S, ≤0.5 μg/ml; intermediate, 1 to 4 μg/ml; R, ≥ 6 μg/ml) were applied to clarithromycin. ND, no MIC data available; NA, no isolates within criteria; −, no defined breakpoints.

  • c Based on oxacillin susceptibility.